

# Development of DWP216, a TEAD1 selective inhibitor for NF2 mutant solid cancer patients

Daewoong Pharmaceutical Co., LTD



ONCOLOGY	Preclinical
Product Type	Small molecule
Indication	Solid tumors
Target	TEAD1
MoA(Mechanism of Action)	TEAD1 selective inhibitor
Competitiveness	<ul style="list-style-type: none"> <li>• DWP216 is a novel TEAD1 selective inhibitor for NF2 mutant cancers.</li> <li>• Most of the TEAD inhibitors currently in development are pan-TEAD inhibitors, which show efficacy but are associated with nephrotoxicity. TEAD1 selective inhibitors, on the other hand, lack sufficient potency.</li> <li>• In an in vivo mouse model, DWP216 is superior to a TEAD1 selective inhibitor, with tumor inhibition equivalent to a pan-TEAD inhibitor.</li> <li>• DWP216 shows a synergistic anti-tumor effect with EGFR inhibitor or KRAS inhibitor</li> </ul>
Development Stage	Preclinical
Route of Administration	Oral administration